Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease

Salivary gland carcinomas (SGC) account for less than 5% of head and neck malignant neoplasms, further subcategorized in over 20 histological subtypes. For the most part, treatment for advanced disease is guided by morphology. SGC in general respond poorly to standard chemotherapy, with short durabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Villeneuve, Larissa, Souza, Ive Lima, Tolentino, Fernanda Davila Sampaio, Ferrarotto, Renata, Schvartsman, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649804/
https://www.ncbi.nlm.nih.gov/pubmed/33194707
http://dx.doi.org/10.3389/fonc.2020.580141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649804/
https://www.ncbi.nlm.nih.gov/pubmed/33194707
http://dx.doi.org/10.3389/fonc.2020.580141

Ejemplares similares